A Step Forward Toward Better Characterization of Ovarian Cancer

Publication
Article
OncologyONCOLOGY Vol 26 No 2
Volume 26
Issue 2

A new study has made a step forward toward better characterization of sporadic ovarian tumors by identifying their DNA repair protein expression profile.

It has been difficult to identify subcategories in ovarian cancer that can be used to tailor treatment. However, a new study has taken a step forward toward better characterization of sporadic ovarian tumors by identifying their DNA repair protein expression profile.

The molecular characterizations of tumor samples from 186 women were analyzed for specific protein expression levels by Tanja Pejovic, a gynecologic oncologist at the Knight Cancer Institute in Portland, Oregon, and colleagues. Their work is published in the Public Library of Science online journal PloS One.[1]

The study shows that patients with simultaneously high expression levels of the DNA repair proteins PARP, FANCD2, and p53 have a higher risk of early ovarian cancer recurrence and resistance to platinum-based chemotherapy.

Ovarian cancer is the most common cause of death among women with a gynecological cancer, with approximately 14,000 ovarian cancer deaths occurring every year and 21,000 new diagnoses. Many patients are not diagnosed with ovarian cancer until an advanced stage of disease. Standard of care is cytoreductive surgery and platinum-based chemotherapy, which has not significantly improved long-term survival.

The study by Pejovic et al shows that patients with simultaneously high expression levels of the DNA repair proteins PARP, FANCD2 (part of the Fanconi’s anemia [FA] gene group), and p53 have a higher risk of early ovarian cancer recurrence and resistance to platinum-based chemotherapy. Patients who had high levels of all three proteins were twice as likely to have earlier recurrence within 3 years compared with all other patients after adjustment for age, cancer status, and time of diagnosis (P = .03).

The authors suggest that dual inhibition of the FA/BRCA pathway and PARP may be effective in these triple-profile ovarian cancers. Poly(ADP ribose) polymerase (PARP) inhibitors emerged as a promising treatment, showing promising results in patients who have BRCA1- or BRCA2-positive ovarian cancer. Approximately 10% to 15% of ovarian tumors harbor germline mutations in either of these two genes, but sporadic mutations in BRCA1 or BRCA2 and other DNA repair genes are also prevalent. As many as 20% of high-grade serous sporadic ovarian tumors have BRCA1 and BRCA2 mutations. The study by Pejovic et al now shows that PARP inhibitors may work in a broader range of ovarian cancers, ones that have mutations in other DNA repair genes besides BRCA1 and BRCA2.

PARP inhibitors are thought to be effective in ovarian cancer because they prevent DNA repair that might otherwise keep cancerous cells alive. The set of DNA repair genes that are mutated, including PARP, PTEN, RAD51, and the FA genes in the tumor is known as its “BRCAness profile.”

The rationale is that adding a PARP inhibitor on top of platinum-based chemotherapy will specifically kill cancer cells that are already sensitive to a platinum treatment regimen. This is the concept of synthetic lethality, according to which targeting two components of the same pathway should result in cell death rather than adaptation because blocking another repair pathway in cells already deficient in DNA repair (that’s the BRCAness profile) and simultaneously increasing DNA damage via platinum-based chemotherapy results in a lethal phenotype. Or at least that is the hope.

The trouble with ovarian tumors is their characteristic genomic instability, which may contribute to evolving mutations in DNA repair genes. The variation in DNA repair genes can influence whether a tumor responds to treatment.

This may be the reason for the recent setbacks in the development of PARP inhibitors. The class of drugs has just not been studied in the correct subpopulation. The PARP inhibitor olaparib had shown promise in a phase II trial, exhibiting a significantly prolonged progression-free survival in patients with platinum-sensitive relapsed serous ovarian cancer, as reported at ASCO last year. Unfortunately, at the end of 2011, the company developing the drug announced that the progression-free survival seen was not likely to translate to an overall survival benefit. The drug was given in combination with a platinum-based chemotherapy regimen; however, patients were not specifically selected based on a BRCAness profile or reduced DNA repair profile of their tumors.

“The judgment on PARP inhibitors in ovarian cancer is still pending. We still do not have all the data we need. Certainly identifying the right group of patients who are likely to benefit from these drugs has been one of the challenges,” Tanja Pejovic commented.

Larger cohort studies that molecularly define ovarian tumors and correlate the profiles to treatment response and recurrence are necessary to better classify ovarian cancers and tailor treatments, as has been done for other types of tumors. The current study only analyzed a subset of DNA repair proteins, while others may play a major role in disease development and response to treatment.

“Identifying alterations in DNA repair proteins beyond BRCA proteins may give access to clinical trials-with PARP inhibitors, for example-to many more women with ovarian cancer,” said Dr. Pejovic.

Dr. Pejovic is already thinking about the next step-to perform functional assays and understand what the differences in protein expression and tumor mutations actually mean for the tumor cell’s ability to repair DNA damage. “We need to perform functional studies to confirm that these patients that we identified with high PARP, FANCD2, and p53 protein expression indeed have defective homologous recombination [HR],” she explained. “The testing for defects in HR has not been standardized, so I am working with a colleague here on developing a RAD51 foci formation test as a surrogate for HR status,” she added.

There have not been many new treatments developed for ovarian cancer in the last 20 years. The molecular characterization of these tumors should facilitate a more targeted approach that may identify the patients who will most benefit from the drugs currently in development for ovarian cancer.

Reference

1.Wysham WZ, Mhawech-Faucedia P, Li H, et al. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One. 2012;7:e30042.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Related Content